Kura Oncology is a La Jolla, California-based clinical-stage biopharmaceutical company led by Troy Wilson, Ph.D., J.D. The company focuses on precision medicines for solid tumors and hematologic malignancies, with tipifarnib as a lead program. Kura entered an exclusive license agreement with Janssen Pharmaceutica NV to develop and commercialize tipifarnib in oncology. Tipifarnib is described as a Phase 2-ready protein farnesyl transferase inhibitor and Kura plans to advance it into Phase 2 trials in 2015, targeting HRAS-driven solid tumors and certain hematologic malignancies. The company will use the proceeds from the financing to develop tipifarnib and support preclinical pipeline programs. Kura also completed a reverse merger to become a public reporting company and intends to register and seek quotation on the OTC Markets.

Total raised

$60M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2015